Oropharyngeal squamous cell carcinoma
Not recruitingStudy Comparing Cisplatin and Radiotherapy with Durvalumab and Radiotherapy for Patients with Intermediate Risk HPV-Positive Oropharyngeal Cancer
Study Comparing Cisplatin and Radiotherapy with Durvalumab and Radiotherapy for Patients with Intermediate Risk HPV-Positive Oropharyngeal Cancer
- Disease:Oropharyngeal squamous cell carcinoma
- Substances:CisplatinDurvalumab
Belgium- Participants:18–64 years · 65+ years
- Substances:Cisplatin
- Sponsor:European Organisation For Research And Treatment Of Cancer











